Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders
The go-to CMC and bioprocessing podcast for process development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.
Practical, execution-focused guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics.
Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.
This podcast is for you if:
- You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership
- You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness
- You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny
- You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources
What you will learn:
CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling and manufacturing economics, continuous manufacturing and Industry 4.0 in biopharma, biologics modalities including mAbs, ADCs, and cell and gene therapies.
Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.
Next Steps:
Book a free assessment to reduce biomanufacturing costs and make lifesaving therapies more accessible: https://bruehlmann-consulting.com/assessment
Fast-track bioprocess development with expert guidance: https://bruehlmann-consulting.com
Visit the Website: https://smartbiotechscientist.com
Email us: hello@bruehlmann-consulting.com
Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders
169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code?
For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powered by advanced mass spectrometry and AI, offering a fuller picture of human health.
In this episode, David Brühlmann meets Mo Jain, founder and CSO of Sapient, a leader in multi-omics analytics. With over two decades of experience across physiology, biomedicine, and computational biology, Mo has been at the forefront of developing scalable multi-omics technologies that are changing the way we predict, diagnose, and treat disease. From leading an academic lab to building a pioneering biotech company, Mo’s journey reflects a passion for uncovering the hidden 80–90% of disease risk that lies beyond our genes.
Here are three reasons you’ll want to listen to this episode:
- Your Environment Matters More Than Your Genes: Mo explains why your zip code is a stronger predictor of your health than your genetic code, challenging the industry’s long-held beliefs and opening new avenues for disease prevention and risk assessment.
- Multi-omics Disrupts Drug Development: Discover how integrating thousands of biological data points can revolutionize drug discovery by identifying novel targets, better predicting drug response, and accelerating therapeutic breakthroughs that were previously out of reach.
- Big Data Finally Becomes Actionable: Thanks to rapid advances in mass spectrometry and computational power, scientists can now make sense of overwhelming volumes of multi-omic data, turning what was once information overload into actionable insights for diagnostics and drug development.
Ready to think beyond your genes? The biotech revolution is here, and it starts in your neighborhood.
Connect with Mo Jain:
LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba
Website: www.sapient.bio
Company LinkedIn Page: https://www.linkedin.com/company/sapientbio
Next step:
Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call
Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech
One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.